Document is current
Any future updates will be listed below
-
Authors
Rosenberg, Noa
Manders, Evert
van den Berg, Sibren
Deesker, Lisa J.
Garrelfs, Sander F.
de Visser, Saco J.
Groothoff, Jaap W.
Hollak, Carla E. M. https://orcid.org/0000-0003-0464-1078
-
Funding
Funding for this research was provided by:
Nationale Postcode Loterij
- License Information
-
More Information
Article History
Received: 17 June 2024
Accepted: 11 November 2024
First Online: 23 December 2024
Declarations
:
: Not applicable.
: Not applicable.
: NR and EM have no conflicts of interest to declare. SB is part of Round table for orphan drugs at the Dutch Healthcare Institute. CEMH is involved in premarketing studies in the field of lysosomal storage disorders with Idorsia and Sanofi for which financial arrangements are made through AMC Research BV. CEMH is part of the Advisory Committee to the Package, Round table for orphan drugs and Horizonscan medicines at the Dutch Healthcare Institute. SV is part of the Board of Governors of European infrastructure for translational medicine (EATRIS) and board member of the Federation for Innovative Drug Research Netherlands (FIGON). LD has received the Travelgrant ERA and international hyperoxaluria workshop. SG received grants from Stichting Metakids and Nierstichting and a speaker’s fee from Alnylam Pharmaceuticals. SG participated in Arbor Pharmaceuticals’ advisory board meeting. JG received grants for registry and stable isotopes studies from Alnylam and NovoNodisk/Dicerna, consulting fees from Alnylam and NovoNordisk and travel support from Alnylam for meetings. JG participates in the Advisory board of Alnylam and NovoNordisk and was chair of OxalEuropa until June 2023.
